StoneX Group’s Vanda Pharmaceuticals VNDA Stock Holding History

StoneX Group’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,000	Closed	-$94.4K	–	1026
2025 Q2	$94.4K	Buy	+20,000	New	+$87.5K	﹤0.01%	811

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

StoneX Group's VNDA Position: Q3 2025 in Review

StoneX Group sold out of Vanda Pharmaceuticals (VNDA) in Q3 2025, closing a stake of 20,000 shares — an estimated $94.4K sold.

StoneX Group first reported a position in VNDA in Q2 2025 and held it in 1 quarter. The position peaked at $94.4K in Q2 2025. 150 funds tracked by Wall St. Rank hold VNDA as of Q3 2025.

StoneX Group reported no remaining Vanda Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
StoneX Group sold 20,000 Vanda Pharmaceuticals shares in Q3 2025, an estimated $94.4K.
StoneX Group first reported a position in Vanda Pharmaceuticals in Q2 2025 and held it in 1 quarter.
StoneX Group's Vanda Pharmaceuticals position peaked at $94.4K in Q2 2025.
150 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2025.

Based on StoneX Group's 13F filing for Q3 2025, filed 14 Nov 2025.